Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: A randomized controlled trial

Nephrology Dialysis Transplantation

Volumn 25, Issue 1, 2010, Pages 129-136

  Hofstra, Julia M ^a   Branten, Amanda J W ^a   Wirtz, Joris J J M ^b   Noordzij, Ton C ^c   Du Buf Vereijken, Peggy W G ^d   Wetzels, Jack F M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LAURENTIUS HOSPITAL   (Netherlands)

^c Franciscus Hospital   (Netherlands)

^d AMPHIA HOSPITAL   (Netherlands)

Author keywords

Cyclophosphamide; Immunosuppressive treatment; Membranous nephropathy; Randomized controlled trial; Renal outcome

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FAMOTIDINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHYLPREDNISOLONE; PREDNISONE; STEROID;

ADULT; ANEMIA; ARTHRALGIA; ARTICLE; BONE MARROW DEPRESSION; CLINICAL ARTICLE; CLINICAL DECISION MAKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY INTERVENTION; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEPATITIS; HIGH RISK PATIENT; HUMAN; HYPERSENSITIVITY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY VEIN THROMBOSIS; LEUKOPENIA; LIVER FUNCTION TEST; LUNG ALVEOLITIS; MALAISE; MALE; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; REMISSION; RESPIRATORY TRACT INFECTION; RISK BENEFIT ANALYSIS; SIDE EFFECT; THERAPY DELAY; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

ADULT; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 72949097419     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp390     Document Type: Article

References (20)

1. du Buf-Vereijken PW, Branten AJW, Wetzels JFM. Idiopathic membranous nephropathy: outline and rationale of a treatment strategy. Am J Kidney Dis 2005; 46: 1012-1029
2. Fervenza FC, Sethi S, Specks U. Idiopathic membranous nephropathy: diagnosis and treatment. Clin J Am Soc Nephrol 2008; 3: 905-919
3. Ruggenenti P, Chiurchiu C, Abbate M et al. Rituximab for idiopathic membranous nephropathy: who can benefit? Clin J Am Soc Nephrol 2006; 1: 738-748
4. Cattran DC. Management of membranous nephropathy: when and what for treatment. J Am Soc Nephrol 2005; 16: 1188-1194
5. Ponticelli C, Zucchelli P, Passerini P et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995; 45: 1600-1604
6. Torres A, Dominguez-Gil B, Carreno A et al. Conservative versus immunosuppressive treatmentofpatients with idiopathic membranous nephropathy. Kidney Int 2002; 61: 219-227
7. Honkanen E, Törnroth T, Grönhagen-Riska C et al. Long-term survival in idiopathic membranous glomerulonephritis: can the course be clinically predicted? Clin Nephrol 1994; 41: 127-134
8. Davison AM, Cameron JS, Kerr DN et al. The natural history of renal function in untreated idiopathic membranous glomerulonephritis in adults. Clin Nephrol 1984; 22: 61-67
9. du Buf-Vereijken PW, Branten AJ, Wetzels JF. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate. Nephrol Dial Transplant 2004; 19: 1142-1148
10. Branten AJW, Reichert LJM, Koene RAP et al. Oral cyclophos-phamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency. Q J Med 1998; 91: 359-366
11. Cattran DC, Pei Y, Greenwood C et al. Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney Ínt 1997; 51: 901-907
12. Reichert LJM, Koene RAP, Wetzels JFM. Urinary excretion of β2-microglobulin predicts renal outcome in patients with idiopathic membranous nephropathy. J Am Soc Nephrol 1995; 6: 1666-1669
13. Branten AJW, du Buf-Vereijken PW, Klasen IS et al. Urinary excretion of β2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: a validation study. J Am Soc Nephrol 2005; 16: 169-174
14. Bazzi C, Petrini C, Rizza V et al. Urinary excretion of IgG and α1-microglobulin predicts clinical course better than extent of protein-uria in membranous nephropathy. Am J Kidney Dis 2001; 38: 240-248
15. Bazzi C, Petrini C, Rizza V et al. Characterization of proteinuria in primary glomerulonephritides. SDS-PAGE patterns: clinical significance and prognostic value of low molecular weight ('tubular') proteins. Am J Kidney Dis 1997; 29: 27-35
16. Branten AJW, du Buf-Vereijken PWG, Vervloet M et al. Mycophe-nolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophos-phamide. Am J Kidney Dis 2007; 50: 248-256
17. Levey AS, Greene T, Kusek JW et al. Simplified equation to predict glomerular filtration rate from serum creatinine (abstract). J Am Soc Nephrol 2000; 11: A0828
18. Ponticelli C, Altieri P, Scolari F et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998; 9: 444-450
19. Jha V, Ganguli A, Saha TK et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 2007; 18: 1899-1904
20. Ueda N. Effect of corticosteroids on some hemostatic parameters in children with minimal change nephrotic syndrome. Nephron 1990; 56: 374-378